Skip to main content
. Author manuscript; available in PMC: 2014 Jul 1.
Published in final edited form as: Cancer Discov. 2013 Apr 4;3(7):782–797. doi: 10.1158/2159-8290.CD-12-0215

Figure 6. Attenuation of DGKα activity has preferential toxicity for cancer cell line.

Figure 6

A, Basal DGKα levels were evaluated by immunoblot in normal human cell lines and various cancer cell lines, with α-tubulin shown as loading control. Cell toxicity was assessed by cell counts/trypan blue in B, A-375 (melanoma), C, HeLa (cervical cancer), and D, MDA-MB-231 (breast cancer) lines 4 days after DGKα knockdown or treatment with R59022 at 10 µM or DMSO vehicle. E, Dose response curves were generated for astrocytes, fibroblasts, U251, U87, A-375, HeLa, MDA-MB-231, and 0308 (GBM stem cell) cells by cell counts and normalized for DMSO (v:v) at 5, 10, 20, 40, 60, 80, and 100 µM R59022 after 4 days of treatment. (*, P<0.05 and **, P<0.01 Student t test)